We develop
cures instead of treatments
About us
Genewity is a pioneering biotech start-up focused on advanced thymus-driven therapies for immune reconstitution. Supported by the extensive business expertise of our management and advisors, we are at the forefront of developing and commercialising breakthrough therapies. With over 150 years of combined experience in immunology and gene therapy, our team is uniquely positioned to drive advancements in the field.
Mission
Our mission is to save and enhance lives by developing cutting-edge autologous gene-modified cell therapies to restore immune function in patients with immune disorders.
Vision
Our vision is to unlock the unrealised potential of restoring immune function to make a difference in the lives of patients worldwide. We pioneer innovative gene-modified cell therapies, bridging academic excellence and clinical application. By leveraging intellectual property, we transfer value and knowledge to set new industry standards with patient-centric treatments and make a global impact.
Supported by
Management & Advisors
Scientific team
Technology
Genewity harnesses cutting-edge biotechnology to develop autologous thymus tissue, aiming to restore the immune system with minimal rejection risk. By targeting underlying thymic defects, our innovative gene modification and cell therapy techniques provide critical solutions for treating severe immune deficiencies. In close collaboration with world leading institutions and industry partners, we focus on rigorous preclinical and clinical research to deliver transformative therapies, enhancing patient well-being and healthcare outcomes.
Product pipeline
Product
i-Thymus
i-TOL
Indications
congenital athymia
undisclosed
Location
EU
EU
Discovery
Preclinical
Phase I/II
Phase III
Product pipeline
Product
i-Thymus
i-TOL
Indications
congenital athymia
undisclosed
Location
EU
EU
Discovery
Product pipeline
Programme
discovery-preclinical-phase1-phase2-phase3
i-Thymus
preclinical stage
i-TOL
discovery stage
News
Careers
There are currently no vacancies.
Open applications welcome
We always welcome open applications. If you are a talented individual interested in contributing to our mission, please send your CV and motivation letter to our CEO at:
a.bisschop@genewity.tech.
a.bisschop@genewity.tech.
About Genewity
Genewity B.V., founded in 2022 and based at BioScience Park in Leiden, the Netherlands, is a pioneering biotech company focused on developing autologous thymus tissue de novo. Our team leverages a wealth of scientific and business experience in cell and gene therapies. Genewity has been awarded several grants, including the prestigious EIC Accelerator. We collaborate in various international consortia with world-renowned partners in academia and industry. Currently in the preclinical development stage, we are raising Series A funding to advance our technology to clinical application.
Contact
If you have any questions, please feel free to contact us at the following email address:
info@genewity.tech